Amicus Therapeutics (FOLD)announced that Simon Harford has been appointed Chief Financial Officer, CFO, effective immediately. Simon brings extensive financial leadership experience, having served in significant finance roles in two global pharmaceutical companies as well as most recently as a public company CFO in the biotechnology industry. Daphne Quimi has decided to retire and will remain an Amicus employee through the end of the year to ensure a smooth transition. Harford brings extensive finance experience in the pharmaceutical and healthcare industry both in the U.S. and internationally. Simon most recently served as Chief Financial Officer of Boston-based biotech Albireo Pharma, a rare pediatric liver disease company, until its sale to Ipsen (IPSEY).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on FOLD:
- Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer
- Amicus announces approval, launch of new Pompe disease therapy in U.K.
- Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
- Amicus reports Q2 EPS (15c), consensus (12c)
- Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates